{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:46Z","timestamp":1793928946551,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41591-025-03969-0","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:04:08Z","timestamp":1761037448000},"page":"4150-4159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-7942","authenticated-orcid":false,"given":"Pablo","family":"Tebas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-9984","authenticated-orcid":false,"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Agnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-3499","authenticated-orcid":false,"given":"Elizabeth M.","family":"Parzych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Caturla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bedanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungdhak","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knashawn","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinah","family":"Amante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-4682","authenticated-orcid":false,"given":"Joseph R.","family":"Francica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-1587","authenticated-orcid":false,"given":"Jesper","family":"Pallesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor R. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"3969_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3969_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3969_CR3","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"A Lee","year":"2022","unstructured":"Lee, A. et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 376, e068632 (2022).","journal-title":"BMJ"},{"key":"3969_CR4","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1093\/cid\/ciab912","volume":"75","author":"M Dougan","year":"2022","unstructured":"Dougan, M. et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin. Infect. Dis. 75, e440\u2013e449 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"3969_CR5","unstructured":"Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Sotrovimab (FDA, 2022)."},{"key":"3969_CR6","unstructured":"Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab (FDA, 2022)."},{"key":"3969_CR7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","volume":"327","author":"A Gupta","year":"2022","unstructured":"Gupta, A. et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 327, 1236\u20131246 (2022).","journal-title":"JAMA"},{"key":"3969_CR8","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3969_CR9","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of COVID-19. N. Engl. J. Med. 386, 2188\u20132200 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3969_CR10","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224\u20132233 (2021).","journal-title":"Nat. Med."},{"key":"3969_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","volume":"28","author":"JP Casazza","year":"2022","unstructured":"Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022\u20131030 (2022).","journal-title":"Nat. Med."},{"key":"3969_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33309-6","volume":"13","author":"EM Parzych","year":"2022","unstructured":"Parzych, E. M. et al. DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. Nat. Commun. 13, 5886 (2022).","journal-title":"Nat. Commun."},{"key":"3969_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2294860","volume":"13","author":"A Patel","year":"2024","unstructured":"Patel, A. et al. In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates. Emerg. Microbes Infect. 13, 2294860 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"3969_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang, J. H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target. Ther. 9, 78 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3969_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3969_CR16","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan, D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol. Ther. 31, 3123\u20133126 (2023).","journal-title":"Mol. Ther."},{"key":"3969_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4049\/jimmunol.2000429","volume":"205","author":"A McNee","year":"2020","unstructured":"McNee, A. et al. Establishment of a pig influenza challenge model for evaluation of monoclonal antibody delivery platforms. J. Immunol. 205, 648\u2013660 (2020).","journal-title":"J. Immunol."},{"key":"3969_CR18","doi-asserted-by":"publisher","first-page":"1017612","DOI":"10.3389\/fonc.2022.1017612","volume":"12","author":"K Hollevoet","year":"2022","unstructured":"Hollevoet, K. et al. Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model. Front. Oncol. 12, 1017612 (2022).","journal-title":"Front. Oncol."},{"key":"3969_CR19","doi-asserted-by":"publisher","first-page":"e1007395","DOI":"10.1371\/journal.ppat.1007395","volume":"14","author":"HC Welles","year":"2018","unstructured":"Welles, H. C. et al. Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog. 14, e1007395 (2018).","journal-title":"PLoS Pathog."},{"key":"3969_CR20","doi-asserted-by":"publisher","first-page":"3072586","DOI":"10.1155\/2016\/3072586","volume":"2016","author":"S Song","year":"2016","unstructured":"Song, S., Yang, L., Trepicchio, W. L. & Wyant, T. Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance. J. Immunol. Res. 2016, 3072586 (2016).","journal-title":"J. Immunol. Res."},{"key":"3969_CR21","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230\u2013e239 (2019).","journal-title":"Lancet HIV"},{"key":"3969_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/19420862.2019.1654304","volume":"11","author":"X Xiao","year":"2019","unstructured":"Xiao, X. et al. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV\/hMPV cross-neutralizing epitopes. MAbs 11, 1415\u20131427 (2019).","journal-title":"MAbs"},{"key":"3969_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","volume":"169","author":"DF Robbiani","year":"2017","unstructured":"Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597\u2013609 (2017).","journal-title":"Cell"},{"key":"3969_CR24","unstructured":"Columvi (glofitamab-gxbm), package insert (Genentech, 2023)."},{"key":"3969_CR25","unstructured":"Blincyto (blinatumomab), package insert (Amgen, 2018)."},{"key":"3969_CR26","unstructured":"Kimmtrak (tebentafusp-tebn), package insert (Immunocore Commercial, 2022)."},{"key":"3969_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41574-024-01066-9","volume":"21","author":"DJ Drucker","year":"2025","unstructured":"Drucker, D. J. Expanding applications of therapies based on GLP1. Nat. Rev. Endocrinol. 21, 65\u201366 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"3969_CR28","unstructured":"US Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (US Department of Health and Human Services, US Food and Drug Administration, Center for Biologics Evaluation and Research, 2007)."},{"key":"3969_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","volume":"227","author":"P Forte-Soto","year":"2023","unstructured":"Forte-Soto, P. et al. Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab-cilgavimab) in healthy adults. J. Infect. Dis. 227, 1153\u20131163 (2023).","journal-title":"J. Infect. Dis."},{"key":"3969_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","volume":"221","author":"A Frey","year":"1998","unstructured":"Frey, A., Di Canzio, J. & Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221, 35\u201341 (1998).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03969-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03969-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03969-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:29Z","timestamp":1765814429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03969-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03969-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6066550\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.B.W. has received grant funding, participates in industry collaborations, has received speaking honoraria and has received fees for consulting, including serving on scientific review committees and board series. Remuneration received by D.B.W. includes direct payments and stock or stock options. D.B.W. also discloses the following paid associations with commercial partners: Geneos (advisory board), AstraZeneca (advisory board, speaker), Inovio (BOD, SRA, stock) and Sanofi (advisory board). J.A., D.A., P.F., L.H. and T.R.F.S. are employees of Inovio Pharmaceuticals; as such, they receive salary and benefits, including ownership of stock and stock options. P.E.L., J.R.F. and M.T.E. are employees of and hold or may hold stock in AstraZeneca. A.P., E.M.P., T.R.F.S, D.W.K. and D.B.W are listed as inventors on patent application no. WO2023064841A1 \u2018Antibodies for use against SARS-COV2\u2019, published 20 April 2023, filed by The Wistar Institute. This application includes the HC and LC plasmid sequences for pAZD8076 HC, pAZD8076 LC, pAZD5036 HC and pAZD5036 LC described in this manuscript. Plasmids are available upon request and completion of a material transfer agreement. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}